Paula Aranaz Oroz-rekin lankidetzan egindako argitalpenak (10)

2017

  1. p.Y317H is a new JAK2 gain-of-function mutation affecting the FERM domain in a myelofibrosis patient with CALR mutation

    Haematologica

2014

  1. A simple approach for classifying new mutations as somatic or germinal in DNA samples lacking paired tissue

    BioTechniques, Vol. 56, Núm. 6, pp. 327-329

  2. Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling

    Leukemia

2013

  1. CBL RING finger deletions are common in core-binding factor acute myeloid leukemias

    Leukemia and Lymphoma

2012

  1. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia

    Leukemia and Lymphoma

  2. CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2

    Haematologica, Vol. 97, Núm. 8, pp. 1234-1241

2011

  1. LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation

    Leukemia Research, Vol. 35, Núm. 11, pp. 1537-1539

2010

  1. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes

    Cancer Genetics and Cytogenetics, Vol. 199, Núm. 1, pp. 1-8

  2. Quantification of PDGFRA alternative transcripts improves the screening for XPDGFRA fusions by reverse transcriptase-polymerase chain reaction

    Leukemia and Lymphoma, Vol. 51, Núm. 9, pp. 1720-1726

2008

  1. Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs

    Leukemia Research